Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?

Area of Science:

• Infectious Diseases
• Immunology
• Pharmacology

Background:

• Clostridium difficile infection (CDI) is a significant healthcare challenge with increasing recurrence rates.
• Current standard-of-care (SoC) antibiotic treatments for CDI do not fully prevent subsequent infections.

Purpose of the Study:

• To review the pharmacology, pharmacokinetics, efficacy, safety, and therapeutic role of bezlotoxumab (BEZ), a monoclonal antibody targeting Clostridium difficile toxin B.
• To evaluate BEZ's potential in preventing recurrent CDI (rCDI).

Main Methods:

• A comprehensive literature search was conducted using PubMed for studies on bezlotoxumab (MK-6072, MDX-1388) and Clostridium difficile.
• The search included English-language studies detailing clinical efficacy, safety, and pharmacokinetics in humans and animals, published between 1946 and April 2017.

Main Results:

• Two Phase III trials (MODIFY I and II) involving over 2600 patients showed a 40% relative reduction in rCDI with BEZ compared to placebo (16.5% vs 26.6%).
• The most frequent adverse events were mild to moderate infusion-related reactions (10.3%).
• BEZ demonstrated efficacy in preventing rCDI but not in treating initial CDI episodes.

Conclusions:

• Bezlotoxumab is an effective adjunctive therapy to SoC antibiotics for preventing recurrent CDI.
• BEZ represents a promising strategy to combat rising CDI rates, particularly for high-risk patient populations.
• Further definition of the optimal patient population for BEZ therapy is warranted.